Table 2 Characteristics at enrolment and ART initiation of adults attending HIV clinics Tanzania by calendar year group
All adults | Adult characteristics by year of enrolment | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
All years | 2005-2007 | 2008-2009 | 2010-2011 | p value for trend | ||||||
N = 58,102 | N = 15,392 | N = 22,289 | N = 20,421 | |||||||
n | (%) | n | (%) | n | (%) | n | (%) | |||
Gender1 | Male | 19467 | (33.5) | 5033 | (32.7) | 7498 | (33.6) | 6936 | (34.0) | 0.02 |
Female | 38634 | (66.5) | 10358 | (67.3) | 14791 | (66.4) | 13485 | (66.0) | ||
Females pregnant at enrolment2 | 4816 | (12.5) | 704 | (6.8) | 1793 | (12.1) | 2319 | (17.2) | <0.0001 | |
Age at enrolment (years) | 15-19 years | 1748 | (3.0) | 399 | (2.6) | 725 | (3.3) | 624 | (3.1) | <0.0001 |
20-29 years | 14985 | (25.8) | 3416 | (22.2) | 5897 | (26.5) | 5672 | (27.8) | ||
30-39 years | 22683 | (39.0) | 6165 | (40.1) | 8733 | (39.2) | 7785 | (38.1) | ||
10-49 years | 12693 | (21.8) | 3838 | (24.9) | 4667 | (20.9) | 4188 | (20.5) | ||
50+ years | 5993 | (10.3) | 1574 | (10.2) | 2267 | (10.2) | 2152 | (10.5) | ||
Point of entry into HIV care | Point of entry documented | 53739 | (92.5) | 13405 | (87.1) | 21027 | (94.3) | 19739 | (92.5) | <0.0001 |
VCT | 28126 | (52.3) | 5035 | (37.6) | 11943 | (56.8) | 11148 | (57.8) | <0.0001 | |
PMTCT | 5311 | (9.9) | 887 | (6.6) | 1993 | (9.5) | 2431 | (12.6) | ||
Other3 | 20295 | (37.8) | 7483 | (55.8) | 7091 | (33.7) | 5721 | (29.6) | ||
Transferred in | Yes | 5398 | (9.3) | 643 | (4.2) | 2720 | (12.2) | 2035 | (10.0) | <0.0001 |
WHO stage at enrolment | WHO stage documented | 49048 | (84.4) | 9545 | (62.0) | 20018 | (89.8) | 19485 | (95.4) | <0.0001 |
I | 12593 | (25.7) | 1615 | (16.9) | 4742 | (23.7) | 6263 | (32.0) | <0.0001 | |
II | 13309 | (27.1) | 1901 | (19.9) | 5117 | (25.6) | 6291 | (32.3) | ||
III | 14368 | (29.3) | 3445 | (36.1) | 6121 | (30.6) | 4802 | (24.6) | ||
IV | 8778 | (17.9) | 2584 | (27.1) | 4038 | (20.2) | 2156 | (11.1) | ||
CD4+ at enrolment4 | CD4+ documented | 24713 | (42.5) | 6093 | (39.6) | 9804 | (44.0) | 8816 | (43.2) | <0.0001 |
(cells/μL) | <50 | 3467 | (14.0) | 981 | (16.1) | 1294 | (13.2) | 1192 | (13.5) | <0.0001 |
50-99 | 2464 | (10.0) | 718 | (11.8) | 918 | (9.4) | 828 | (9.4) | ||
100-199 | 4494 | (18.2) | 1241 | (20.4) | 1737 | (17.7) | 1516 | (17.2) | ||
200-349 | 5113 | (20.7) | 1217 | (20.0) | 2044 | (20.8) | 1852 | (21.0) | ||
≥350 | 9175 | (37.1) | 1936 | (31.8) | 3811 | (38.9) | 3428 | (38.9) | ||
ART eligibility at enrolment5 | Eligible | 18464 | (31.8) | 5273 | (34.3) | 7601 | (34.1) | 5590 | (27.4) | <0.0001 |
Not eligible | 26151 | (45.0) | 4373 | (28.4) | 10059 | (45.1) | 11719 | (57.4) | ||
Unknown eligibility | 13487 | (23.2) | 5746 | (37.3) | 4629 | (20.8) | 3112 | (15.2) | ||
CD4+ at ART initiation4, (cells/μL) | CD4+ documented | 17142 | (29.5) | 5086 | (33.0) | 6945 | (31.2) | 5111 | (25.0) | <0.0001 |
<50 | 3379 | (19.7) | 1020 | (20.1) | 1307 | (18.8) | 1052 | (20.6) | <0.0001 | |
50-99 | 2597 | (15.1) | 803 | (15.8) | 982 | (14.1) | 812 | (15.9) | ||
100-199 | 5319 | (31.0) | 1638 | (32.2) | 2132 | (30.7) | 1549 | (30.3) | ||
200-349 | 4421 | (25.8) | 1255 | (24.7) | 1888 | (27.2) | 1278 | (25.0) | ||
≥350 | 1426 | (8.3) | 370 | (7.3) | 636 | (9.2) | 420 | (8.2) | ||
Started ART | All adults who started ART | 28578 | (49.2) | 9304 | (60.4) | 11164 | (50.1) | 8110 | (39.7) | <0.0001 |
Females who started ART6 | 18445 | (64.5) | 6190 | (66.5) | 7199 | (64.5) | 5056 | (62.3) | <0.0001 | |
Pregnant at ART initiation7 | 504 | (2.7) | 111 | (1.8) | 211 | (2.9) | 182 | (3.6) | <0.0001 | |
First ART regimen8 | Stavudine containing | 16635 | (58.2) | 7900 | (84.9) | 7139 | (63.9) | 1596 | (19.7) | <0.0001 |
Zidovudine containing | 11086 | (38.8) | 1338 | (14.4) | 3894 | (34.9) | 5854 | (72.2) | ||
Other9 | 857 | (3.0) | 66 | (0.7) | 131 | (1.2) | 660 | (8.1) | ||